THE CONTRIBUTION OF CARRIER THE ALLELIC VARIANT G1691A OF THE GENE V OF COAGULATION FACTOR TO THE DEVELOPMENT OF THROMBOTIC COMPLICATIONS DEPENDING ON THE PRESENCE OF CARDIOVASCULAR RISK FACTORS IN INDIVIDUALS WITH SECONDARY LEUKOCYTOSIS, THROMBOCYTOSIS A
ARTICLE PDF (Українська)

Keywords

allele G1691A the coagulation factor V gene (factor V Leiden), thrombotic complications, reactive thrombocytosis, reactive leukocytosis, secondary polycythemia

How to Cite

Mishcheniuk, O. Y., Kostiukevych, O. M., Benkovska, L. K., & Kravchenko, A. N. (2019). THE CONTRIBUTION OF CARRIER THE ALLELIC VARIANT G1691A OF THE GENE V OF COAGULATION FACTOR TO THE DEVELOPMENT OF THROMBOTIC COMPLICATIONS DEPENDING ON THE PRESENCE OF CARDIOVASCULAR RISK FACTORS IN INDIVIDUALS WITH SECONDARY LEUKOCYTOSIS, THROMBOCYTOSIS A. Clinical and Preventive Medicine, (3-4), 61-67. https://doi.org/10.31612/2616-4868.3(9).2019.08

Abstract

Introduction. In addition to the "Classical" Risk Factors (RF) for Arterial and Venous Thrombosis, some authors, as triggers for the development of the latter, refer to reactive changes in Peripheral Blood (PB) counts and markers of Hereditary Thrombophilia. The results of most studies indicate that the "Classical" Risk Factors (RF) for Vascular Thrombotic Episodes are strong triggers of their development, the presence of which eliminates the Pro-thrombogenic potential of carrier of the Hereditary Thrombophilia and reactive changes in Peripheral Blood (PB) (RChPB). However, to date, there is no data regarding the assessment of contribution of the Leiden Mutation in the cohort with both reactive changes in Peripheral Blood (PB) and Risk Factors (RF) for Thrombotic Complications (ThC).

Results. In patients with reactive changes in the Peripheral Blood (PB), the Leiden Mutation occurs in 5,92% of cases (9 carriers). In individuals with Thrombotic Complications (ThC), the Allele G1691A of the Proaccelerin Gene is determined more often than in a cohort without them (5 out of 31 vs 4 out of 121; p=0,030). In the general cohort of individuals with reactive changes in Peripheral Blood (PB), carriage of the Leiden Mutation increased the risk of Thrombotic Complications (ThC) by 3,05 times (Relative Risk (RR) = 3,05; 95% Confidence Interval (CI) = 1,54-6,03). In patients without Risk Factors (RF) and people under 60 years of age, Thrombosis occurred more often with the Nucleotide Variant of Allele G1691A of the Gene V of Coagulation Factor than with the Allele of wild-type (3 out of 6 vs 4 out of 75; p=0,007 and 4 out of 6 vs 8 out of 107; p=0,010, respectively). The probability of developing of Thrombosis with carriage the Allele G1691A of the Proaccelerin Gene in patients with Thrombotic Complications (ThC) without Risk Factors (RF) and in younger patients was 10,57
(95% Confidence Interval (CI) = 2,60-42,87) and 16,83 times (95% Confidence Interval =
3,43-82,41), respectively. The risk of Thrombotic events in people without Risk Factors (RF) younger than 60 years is 16,75 times (Relative Risk (RR) = 16,75; 95% Confidence Interval
(CI) = 3,44-81,50). However, the frequency and risk of Thrombosis did not increase in individuals with Risk Factors (RF), in patients over 60 years of age or in a cohort with Risk Factors over 60 years of age.

Conclusion. Carriage the Allele G1691A of the Gene V of Coagulation Factor in patients with reactive Thrombocytosis, Leukocytosis and Secondary Polycythemia increases the risk of Thrombosis primarily due to patients without Risk Factors (RF) younger than 60 years.

https://doi.org/10.31612/2616-4868.3(9).2019.08
ARTICLE PDF (Українська)

References

Baglin T., Gray E., Greaves M. (2010). Br. J. Haematol. Clinical guidelines for testing for heritable thrombophilia, 149, 209–220.

De Stefano V., Za T., Rossi E. (2009). Haematologica. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia, 94, 733-737.

Gandrille S., Alhenc-Gelas M., Aiach M. (1995). Blood Coagul. Fibrinolysis. A rapid screening method for the factor V Arg506>Gln mutation, 6 (3), 245-248.

Giri S., Dilipbhai Mehta K. Vijaya R. (2016). Secondary Polycythemia and the Risk of Venous Thromboembolism (VTE) Among Hospitalized Patients in the United States. Bhatt Blood, 128, 1427.

Grau A. J., Boddy A. W., Dukovic D. A., Buggle F., Lichy C., Brandt T., Hacke W. (2004). Leukocyte count as an independent predictor of recurrent ischemic events. Stroke, 35, 1147–1152.

Grody. W., Matteson C., Palomaki G. (2002). American College of Medical Genetics. Standards and Guidelines for Clinical Genetics Laboratories 2006 Edition. Technical Standards and Guidelines: Venous Thromboembolism (Factor V Leiden and Prothrombin 20210G>A Testing): A Disease-Specific Supplement to the Standards and Guidelines for Clinical Genetics Laboratories. Available from http://www.acmg.net/Pages/ACMG_Activities/stds-2002/fv-pt.htm.

Gupta N., Khan F., Tripathi M. (2003). Absence of factor V Leiden (G1691A) mutation, FII G20210A allele in coronary artery disease in North India. IJMS, 57 (12), 535-542.

Ho KM1, Yip CB, Duff O. J. (2012). Reactive thrombocytosis and risk of subsequent venous thromboembolism: a cohort study. Thromb Haemost. 10(9), 1768-74. doi: 10.1111/j.1538-7836.2012.04846.x.

Lane D. Grant P. (2000). Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease Blood., 95, 1517-1532.

Noelia Vilalta, Miquel Vázquez-Santiago, Biel Cuevas, Raquel Macho, Angel Remacha, Marina Carrasco, José Mateo, Juan Millón, José Manuel Soria, Juan Carlos Souto (2017). The Relationship between Leukocyte Counts and Venous Thromboembolism: Results from RETROVE Study., Biol Med (Aligarh), 9,4. DOI: 10.4172/0974-8369.1000400.

Segal J., Brotman D., Necochea A. (2009). Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults With Venous Thromboembolism and in Family Members of Those With a Mutation. JAMA, 301, 2472-2485.

Van de Water F. J., Lund M. (2000). Van de Water F. J. Inherited Thrombophilias and MI, 36, 717-722.

Walker I., Greaves M., Preston F. (2001). Guideline Investigation and management of heritable thrombophilia. Br. J. Haematol., 114, 512-528.

Zoller B., Svensson P., He X. (1994). Identification of the same factor V genemutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J. Clin. Invest., 94, 2521-2524.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.